SGLT2 Is are drugs used for the treatment of T2DM that have demonstrated significant efficacy in reducing cardiovascular events and deaths, even in patients with HF, and have therefore been rapidly incorporated into treatment guidelines for both diabetic and HF patients [159,160]. This evidence concerns the gene SLC5A2 and hydrops fetalis.